Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Phase 2 Study ofVS-6766 +/- Defactinib in Ovarian Cancer

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer

Disease Types: Ovarian

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

For more information:

https://clinicaltrials.gov/ct2/show/NCT04625270?term=A+Phase+2+Study+of+VS-6766+%28Dual+RAF%2FMEK+Inhibitor%29+Alone+and+In+Combination+with+Defactinib+%28FAK+Inhibitor%29+in+Recurrent+Low-Grade+Serous+Ovarian+Cancer&draw=1&rank=1